Abstract:
Micro-Abstract We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy in women >65 years of age with early breast cancer. Elderly breast cancer patients derive clinical benefit comparable with that of younger patients, mainly at the cost of increased risk of hematological toxicity. © 2015 Elsevier Inc.
Notes:
Cited By :1Export Date: 18 February 2017References: Yancik, R., Ries, L.A., Aging and cancer in America. Demographic and epidemiologic perspectives (2000) Hematol Oncol Clin North Am, 14, pp. 17-23;Freedman, R.A., Treatment of breast cancer in the elderly (2015) Curr Oncol Rep, 17, p. 51;
Malik, M.K., Tartter, P.I., Belfer, R., Undertreated breast cancer in the elderly (2013) J Cancer Epidemiol, 2013, p. 893104;
van de Water, W., Bastiaannet, E., Scholten, A.N., Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis (2014) Ann Surg Oncol, 21, pp. 786-794;
Gennari, R., Curigliano, G., Rotmensz, N., Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients (2004) Cancer, 101, pp. 1302-1310;
Du, X.L., Jones, D.V., Zhang, D., Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women (2005) J Gerontol A Biol Sci Med Sci, 60, pp. 1137-1144;
Moylan, E.J., Connell, L.C., O'Reilly, S., Are dose-dense and triplet chemotherapy regimens optimal adjuvant therapy in the majority of women with node-positive early breast cancer? (2014) J Clin Oncol, 32, pp. 605-606;
Muss, H.B., Berry, D.A., Cirrincione, C., Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B (2007) Experience. J Clin Oncol, 25, pp. 3699-3704;
Zauderer, M., Patil, S., Hurria, A., Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer (2009) Breast Cancer Res Treat, 117, pp. 205-210;
Kummel, S., Krocker, J., Kohls, A., Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial (2006) Crit Rev Oncol Hematol, 58, pp. 166-175;
Fountzilas, G., Skarlos, D., Dafni, U., Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group (2005) Ann Oncol, 16, pp. 1762-1771;
Fountzilas, G., Dafni, U., Gogas, H., Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 (2008) Ann Oncol, 19, pp. 853-860;
Gogas, H., Dafni, U., Karina, M., Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial (2012) Breast Cancer Res Treat, 132, pp. 609-619;
Fountzilas, G., Dafni, U., Papadimitriou, C., Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial (2014) BMC Cancer, 14, p. 515;
Hudis, C.A., Barlow, W.E., Costantino, J.P., Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system (2007) J Clin Oncol, 25, pp. 2127-2132;
Gray, R., A class of K-sample tests for comparing the cumulative incidence of a competing risk (1988) Ann Stat, 16, pp. 1141-1154;
Muss, H.B., Adjuvant treatment of elderly breast cancer patients (2007) Breast, 16, pp. S159-S165;
Crivellari, D., Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group (2002) Tumori, 88, pp. S81-S82;
Du, X.L., Lairson, D.R., Begley, C.E., Fang, S., Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort (2005) J Clin Oncol, 23, pp. 8620-8628;
Petrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V., Barni, S., Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis (2012) Breast Cancer Res Treat, 135, pp. 335-346;
Patt, D.A., Duan, Z., Fang, S., Hortobagyi, G.N., Giordano, S.H., Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk (2007) J Clin Oncol, 25, pp. 3871-3876;
Robson, D., Verma, S., Anthracyclines in early-stage breast cancer: is it the end of an era? (2009) Oncologist, 14, pp. 950-958;
Harder, H., Ballinger, R., Langridge, C., Ring, A., Fallowfield, L.J., Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making (2013) Psychooncology, 22, pp. 2729-2735;
Cappellani, A., Di Vita, M., Zanghi, A., Prognostic factors in elderly patients with breast cancer (2013) BMC Surg, 13, p. S2;
Barni, S., Cabiddu, M., Petrelli, F., Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls (2010) Exp Rev Anticancer Ther, 10, pp. 185-198
Website
